The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) Working Group has developed standardized templates for benefit-risk assessments of new vaccine candidates.
(1 - 12 of 17)
This manuscript uses the BRAVATO template to report the key considerations for a benefit-risk assessment of the coronavirus disease 2019 (COVID-19) mRNA-based vaccine[...]
This paper uses a BRAVATO protein template to review the features of Novavax’s recombinant adjuvanted spike protein vaccine to prevent disease caused by[...]
Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has[...]
Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology[...]
Replication-incompetent adenoviral vectors have been under investigation as a platform to carry a variety of transgenes, and express them as a basis for vaccine development.[...]
The Modified Vaccinia Ankara (MVA) vector system is being explored as a platform for development of multiple vaccines. This paper reviews the molecular and biological[...]
This paper uses a BRAVATO protein template to review the features of Medigen’s recombinant SARS-CoV-2 spike protein in prefusion stabilized form used to[...]
The Brighton Collaboration Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO) was formed to evaluate the safety and other key features of new platform[...]
This paper uses the BRAVATO inactivated virus vaccine template to review the features of an inactivated whole chikungunya virus (CHIKV) vaccine that has been evaluated in several preclinical[...]
This paper uses a BRAVATO nucleic acid template to review the features of Moderna’s rapid-response proprietary vaccine platform based on an mRNA delivery[...]
Auro Vaccines LLC has developed a protein vaccine to prevent disease from Nipah and Hendra virus infection that employs a recombinant soluble Hendra glycoprotein (HeV-sG) adjuvanted with aluminum[...]
Several inactivated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration (BC)Â Benefit-Risk Assessment of VAccines by TechnolOgy (BRAVATO), as[...]
Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030